Enveric Biosciences, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Enveric Biosciences, Inc. (ENVB) on September 2, 2025. The report discloses a change in the Company's principal executive office address and references a press release issued on the same date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is an event disclosure and does not contain financial statements or performance metrics.
Material Changes
- Office Relocation: Effective September 2, 2025, the Company changed its principal executive office address to 245 First Street, Riverview II, 18th Floor, Cambridge, MA 02142.
Guidance, Outlook, and Risks
The filing references a press release (Exhibit 99.1) regarding matters disclosed under Item 7.01 (Regulation FD Disclosure). However, the specific content of the press release, including any guidance, outlook, management commentary, or risks, is not included in the provided text. The filing explicitly states that the information furnished is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Facts for Investor Verification
- Verify the full content of the press release dated September 2, 2025 (Exhibit 99.1) to understand the context of the Regulation FD disclosure.
- Confirm the new principal executive office address: 245 First Street, Riverview II, 18th Floor, Cambridge, MA 02142.
- Note that no financial data or operational metrics are contained within this specific filing.